EU HTA Regulation: Companies Can Talk To National Authorities As ‘Substitute’ For EU-Level Advice

 
• By Eliza Slawther
  
Stefano Benvenuti, Henriette Burghoorn, Paolo Morgese, Marcus Droege, Stijn Heessen and Alexander Natz at the Advanced Therapies Congress in London, 2025 (Norstella)

More from Health Technology Assessment

More from Rare Diseases